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This work presents the development of a methodology based on the formation of a charge transfer 
complex between quinalizarin and rosuvastatin, allowing for the spectrophotometric determination of 
rosuvastatin at 579 nm. The factors involved in the sensitivity of the technique were studied (nature 
and proportion of the solvent, reaction time, pH of aqueous phase and quinalizarin concentration). The 
proposed spectrophotometric procedures were validated with respect to linearity, ranges, precision, 
accuracy, detection and quantification limits. Calibration curves of the formed color products showed 
good linear relationships over the concentration range of 6-15 mg L-1. The proposed method has been 
successfully applied, which can be confirmed by interference test (comparison between the standard 
curves and addition of analyte), method precision (RSD 2.3% to 6 mg L-1), and by accuracy (statistically 
equivalent results between the proposed method and a chromatographic method of reference).
Keywords: Rosuvastatin/spectrophotometric determination. Rosuvastatin/charge transfer complex. 
Quinalizarin/charge transfer complex. Pharmaceutical formulations.
INTRODUCTION
Cardiovascular diseases, defined as diseases that 
affect the heart and blood vessels, are the leading cause 
of death worldwide. These diseases manifest in various 
ways, one of which being coronary artery disease, which 
leads to acute myocardial infarction. In this case, there is 
a progressive accumulation of lipid material on the wall 
of the arteries that supply blood to the heart, leading to 
their strengthening due to so-called atheroma plaques 
(Brats, 2009).
Concerns about these diseases are not new, and 
have led to the development of many drugs in an attempt 
to reduce the associated risks. One noteworthy class of 
drugs in this regard is composed of statins, which have 
revolutionized the prevention of cardiovascular diseases 
and are currently the most prescribed drugs in these 
cases. They act by inhibiting 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase, which is important 
in the synthesis of intracellular cholesterol in hepatocytes 
(Campo, Carvalho, 2007).
Many drugs belonging to this this class are registered 
with the Food And Drug Administration (FDA) and differ in 
terms of potency and pharmacological profile. One of them 
is rosuvastatin (RSV) (Figure 1), which represents a new 
class of synthetic statins, with enantiomeric purity (Campo, 
Carvalho, 2007).
Rosuvastatin ((3R,5S,6E)-7-[4-(4-fluorophenyl)-
6-(1-methylrthyl)-2-[methyl(methylsulfonyl)amino]-
5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid) was 
approved in 2003 by the FDA and is sold by AstraZeneca 
as Crestor®. It is sparingly soluble in water and methanol 
and slightly soluble in ethanol (The Merck Index, 2006).
Some methods have been developed for the 
quanti tat ion of  rosuvastat in in pharmaceutical 
FIGURE 1 - Molecular structure of rosuvastatin.
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formulations. Ramadan, Mandil and Alshelhawil (2014) 
developed a spectrophotometric method based on a 
derivatization reaction of rosuvastatin with iodine, as 
well as an electrochemical method based on differential 
pulse polarography using a dropping mercury electrode 
(Ramadan, Mandil, Ghazal, 2015). In addition, some 
methods based on chromatographic separation have also 
been proposed (Beludari, Prakash, Mohan, 2013; Purkar 
et al., 2014).
Alzoman et al. (2013) and Wani et al. (2013) 
developed and applied a spectrophotometric method 
based on the charge transfer reaction between calcium 
rosuvastatin and π acceptors (Alzoman et al., 2013; 
Wani et al., 2013). El-Bagary also proposed a method 
for the determination of this drug (El-Bagary, Elkady, 
Kadry, 2012) in pharmaceutical preparations based on 
spectrophotometric determinations.
In urine, Silva et al. proposed an electrochemical 
methodology using carbon nanotubes and graphene oxide 
as the electrode material (Silva et al., 2015), while Braga 
et al proposed a fluorimetric determination method after 
liquid-liquid extraction (Braga et al., 2013).
The present study reports the development of a 
spectrophotometric method for the determination of 
rosuvastatin in pharmaceutical formulations by employing 
a charge transfer reaction with quinalizarin. This reaction 
leads to the formation of a colored complex, which is 
the result of the interaction between a donor, in this case 
rosuvastatin, and an electron acceptor, quinalizarin, 
(Mostafa, El-Sadek, Alla, 2002) that absorbs in the visible 
region of the eletromagnetic spectrum and posses a high 
molar absorptivity coefficient (Arslan, Duymus, 2007; 
Alzoman et al., 2013). The anion radical, resulting from 
the reaction between the drug and quinalizarin, absorbs 
radiation at a wavelength of 579 nm. This method has 
the advantage of assessing the reaction product in an area 
where less interferences from other substances are present, 
such as in the ultraviolet region.
The methodology was applied to the quantification 
of rosuvastatin in pharmaceutical formulations acquired 
from a local market in Niterói City (RJ/Brazil). The 
results were compared with a reference methodology 
(HPLC-UV). To the best of our knowledge, this is the 
first study on the determination of rosuvastatin using 
quinalizarin.
MATERIAL AND METHODS
Instrumentation
The spectrophotometric measurements were 
conducted on an Agilent Technologies Cary 60 UV-
Vis spectrophotometer, in scanning mode, from 200 
to 800 nm. Quartz cuvettes with an optical path of 1 
cm were employed. The maximum wavelength set for 
checking absorbance was 579 nm. For the comparative 
chromatographic methodology, a 3000 HPLC from 
Dionex, with injection volume of 20 µL and UV detector 
set at 241 nm were used. The mobile phase consisted of 
a mixture 60/40 (v/v) acetonitrile/water with pH adjusted 
to 2.9 with phosphoric acid, at a flow rate of 1 mL min-1. 
A C-18 column (150 x 4.6 mm, 4 mm) from Phenomenex 
was used. The temperature was maintained at 30 °C. The 
mobile phase was sonicated for 20 min in an USC-1600 
ultrasound (Unique, São Paulo, Brazil).
An analytical AY 220 balance (Shimadzu, São 
Paulo, Brazil) was used for the preparation of all solutions. 
An ADM-22 model pH meter (Digimed, São Paulo, Brazil) 
equipped with a combination electrode glass (Ag/AgCl) 
was used for the pH evaluations.
Reagents and solutions
All reagents were of analytical grade. All solutions 
were prepared using purified water obtained by a Millipore 
Direct-Q System 3 (Milford, USA), with resistivity of 
18.2 MΩ cm.
The rosuvastatin standard was provided by 
Neopharma (Minas Gerais, Brazil). The methanolic 
200 mg L-1 stock solution used in the spectrophotometric 
methodology was prepared by dissolving 20.83 mg 
of rosuvastatin calcium in a 100 mL volumetric flask, 
subsequently adjusted to 100 mL with methanol.
For the confirmatory chromatographic methodology, 
the 200 mg L-1stock solution was prepared in the same 
way, with final volume adjustment by the addition of a 
(60/40) acetonitrile solution, with subsequent addition of 
phosphoric acid to pH 2.9. This solution was then filtered 
through a Millipore Millex – GV hydrophilic PVDF 
membrane, with 0.22 µm pore size.
Quinalizarin was provided by Acros Organics (St. 
Louis, USA). The quinalizarin 500 mg L-1 stock solution 
was prepared by dissolving 25 mg of quinalizarin in 
dimethylsulfoxide (DMSO) (Tedia, Brazil) with final 
volume adjusted with the same solvent in a 50 mL 
volumetric flask.
Analytical curves
The analytical curve used in the spectrometric 
methodology was prepared by dilutions of a 200 mg 
L-1 RSV stock solution, in 5.0 mL volumetric flasks. 
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The concentrations ranged from 6.0 to 15 mg L-1. The 
final volume was adjusted by adding water. For the 
comparative chromatographic study, the analytical curve 
was prepared by the dilution of the same stock solution in 
10 mL volumetric flasks, with the final volume adjusted 
by adding the 60/40 acetonitrile/phosphoric acid pH 2.9 
solution. This curve was prepared in the range from 0.5 
to 2.5 mg L-1.
Sample preparation
The samples submitted to the quantification process 
were acquired from local markets in the city of Niterói - 
RJ. Three of the samples (A1, A2 and A3) had an RSV 
amount per tablet of 10 mg, while sample A4 had 20 mg, 
as stated by the manufacturers.
Two tablets from each sample were taken, weighed 
and subsequently crushed with a mortar and pestle. An 
aliquot of each was taken, weighed and transferred to a 
50 mL flask, where they were solubilized with methanol 
and filtered through a Millipore Millex – GV, hydrophilic 
PVDF membrane (0.22 µm pore size), into a 25.0 mL 
volumetric flask, followed by 400 µL of the 500 mg 
L-1quinalizarin solution, 3.75 mL of DMSO and 600 µL of 
water. The final volume was adjusted with methanol. These 
solutions were then analyzed spectrophotometrically at 
579 nm.
For the comparative HPLC methodology, the solid 
aliquots were solubilized in the acetonitrile/phosphoric 
acid (pH 2.9) 60/40 solution and filtered in the same way 
as described above.
RESULTS AND DISCUSSION
The proposed method optimization was carried 
out in 3 steps. In the first step, variables such as solvent, 
time, pH, and the proportion of DMSO/quinalizarin were 
optimized. The stoichiometry of the reaction between 
rosuvastatin and quinalizarin was then evaluated by molar 
ratio calculations. The third step evaluated the possibility 
of matrix interferences.
After method optimization, the determination 
of rosuvastatin in pharmaceutical formulations was 
conducted, with the results subsequently compared to an 
alternative method.
In preliminary studies, the influence of time was 
evaluated and no significant alterations were observed 
in a timeframe of 15 to 6 hours. This indicates that time 
does not influence the analytical signal, suggesting that 
the reaction is fast and that the formed product does not 
degrade.
Nature of the solvent
The first studied parameter was the effect of the 
nature of the solvent. The solvent acts in promoting the 
stabilization of the radical anion formed upon the charge 
transfer reaction, as well as in stabilizing the complex. It is 
worth emphasizing that polar solvents facilitate this charge 
transfer reaction (Basavaiah, 2004). Thus, the evaluated 
solvents were: DMSO, methanol, ethanol and acetonitrile 
(ACN). All the solutions were prepared at a 50% solvent, 
50% water ratio. The results are displayed in Figure 2.
The best analytical signal was attained with the use 
of DMSO. This is probably due the fact that this solvent 
has the highest dielectric constant among the tested 
solvents (The Merck Index, 2006), which provides the 
best conditions for stabilizing the anion radical formed in 
the charge transfer reaction. Thus, DMSO was chosen as 
the solvent in all subsequent assays.
Figure 3 displays the rosuvastatin, quinalizarin and 
the charge transfer complex absorption spectra in DMSO 
50% v/v solutions. Quinalizarin shows an absorption band 
at 486 nm, while the complex shows an absorption band 
at 579 nm. Rosuvastatin (colorless) shows only one band 
at 308 nm.
pH effect
The study of pH is important because both the 
analyte, rosuvastatin, and the reagent, quinalizarin, show 
different equilibria as a function of pH (Yamini et al., 
FIGURE 2 - Effect of the solvent on the analytical signal. 
Conditions: quinalizarin: 30 mg L-1; rosuvastatin: 20 mg L-1 in 
50% water solution.
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2002). To evaluate the pH effect, different solutions of the 
anion radical were prepared in different pHs, adjusted by 
adding the Britton-Robbinson buffer. The condition that 
provided the best analytical signal was no pH adjustment 
at all (pH 5.5). To guarantee that the absence of the buffer 
would not produce a calibration problem, the pH of a 
sample solution was prepared, and exactly the same value 
observed for the samples was found.
DMSO/Water proportion
The reaction between rosuvastatin and quinalizarin 
requires DMSO to stabilize the anion radical, but also 
requires another solvent, since rosuvastatin was separated 
by the most of the excipients of the pharmaceutical 
formulation by solid-liquid extraction in methanol, 
followed by filtration. As this extract is miscible with 
water, the effect of the DMSO/water ratio on the analytical 
signal was investigated.
The results of this investigation are displayed in 
Figure 4. The proportion of 75% DMSO and 25% water 
was chosen, since the increase in the analytical signal from 
that value onwards was insignificant.
Study of quinalizarin concentration influence
The influence of quinalizarin concentrations on 
the analytical signal was also investigated. The results 
displayed in Figure 5 indicate that the analytical signal 
increased until reaching a plateau, beginning at 30 mg 
L-1. This maximum is probably due to the end of the 
reaction. To ensure sufficient robustness, the quinalizarin 
concentration used in all further assays was 40 mg L-1.
Study of the reaction stoichiometry
The stoichiometry of the reaction between 
rosuvastatin and quinalizarin was evaluated by the 
molar ratio technique, developed by Yo and Jones (Yoe, 
Jones, 1944). Several solutions of the complex were 
prepared, with constant rosuvastatin concentration, while 
quinalizarin concentrations ranged from 0 to 70 mg L-1. 
The absorbances of the solutions were measured and the 
results are displayed in Figure 6.
FIGURE 3 - Absorption spectra of rosuvastatin 20 mg L-1, 
quinalizarin 40 mg L-1 and the radical anionic, all DMSO in 
solutions.
FIGURE 4 - Investigation of the DMSO/Water proportion effect 
on the analytical signal. Experimental conditions: quinalizarin: 
30 mg L-1; rosuvastatin: 20 mg L-1.
FIGURE 5 - Study of the effect of quinalizarin concentrations 
on the analytical signal. Experimental conditions: rosuvastatin: 
20 mg L-1 in DMSO: 75% (v/v).
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The condition that provided the higher analytical 
signal was shown to be two quinalizarin for each 
rosuvastatin, corroborating other studies in the literature 
for other charge transfer reactions with quinalizarin (Paula, 
Almeida, Cassella, 2010; Gouda, El-Sheikh, El-Azzazy, 
2012).
Method evaluation
Analytical parameters of merit
Partial validation, as the establishment of some 
analytical parameters of merit is called, is performed 
in order to ensure that the method produces reliable 
information (Ribani et al., 2004). This is conducted 
during and after the optimization of all investigated 
variables. In the present study case, the parameters of 
merit obtained were linear response range (linearity), 
repeatability (precision), limit of detection (L.O.D), limit 
of quantitation (L.O.Q.) and accuracy.
Linearity
The linear response range between the analytical 
signal and the rosuvastatin concentration was obtained by 
constructing a calibration curve from 6.0 to 15.0 mg L-1 
(Figure 7).
Precision
The precision was evaluated by the measurement 
of 10 standard solutions of the complex, prepared at 6.0 
mg L-1, and was of 2.3%, expressed as relative standard 
deviation (RSD).
The standard deviation of the relative value obtained 
for this solution indicates that the developed method has 
adequate precision, since, according the most of references 
which deals with the validation of analytical RSD values 
higher than 5% are not acceptable (FDA, 2015; Ermer, 
Miller, 2006; ANVISA, 2003)
Limit of Detection (L.O.D) and Limit of Quantification 
(L.O.Q)
The limit of detection (LOD) and the limit of 
quantification (LOQ) were calculated according equations 
(1) and (2), where “s” is the standard deviation of 10 
measurements of the blank, and “S” is the angular 
coefficient of the linear equation.
L.O.D. = 3σ/S (Equation 1)
L.O.Q. = 10 σ/S (Equation 2)
The L.O.D. obtained was 0.9, while the L.O.Q was 
3.0 mg L-1.
Study of interferences
One of the reasons that methanol is used in the 
extraction of process of RSV from the pharmaceutical 
formulation is due to the fact that RSV solubility is higher 
in this solvent than in water, while the solubility of the 
excipients is lower in methanol compared to water. Of 
the several compounds used as vehicles present in the 
pharmaceutical formulation evaluated in the present study, 
only lactose is methanol-soluble. 
The interference of different lactose concentrations 
FIGURE 6 - Aplication of the molar ration technique to determine 
the stoichiometry of the charge transfer reaction. Experimental 
conditions: rosuvastatin: 20 mg L-1 and DMSO: 75% (v/v).
FIGURE 7 - Analytical curve for the determination of rosuvastin 
using the charge transfer reaction. Experimental conditions: 
quinalizarin: 40 mg L-1; rosuvastatin: 20 mg L-1 and DMSO 
75% (v/v).
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(1.0 x 10-4 to 1.0 x 10-2 mol L-1) in the formation of the 
charge transfer complex was evaluated, and results 
indicate that this compound does not interfere in the 
reaction.
Comparisons were also conducted between an 
analytical curve and an analyte addition curve for all 
investigated samples. As displayed in Table I, the analyte 
addition curve showed the same angular coefficient of the 
analytical curve, demonstrating that this methodology is 
not susceptible to matrix interferences. 
Application of the developed method for the 
determination of rosuvastatin in pharmaceutical 
formulations and comparison with a chromatographic 
methodology
As the proposed method is free from matrix 
interferences, the developed methodology was applied to 
the determination of rosuvastatin in samples prepared as 
described in section 2.3.
To calculate the accuaracy of the proposed method, 
the same samples analyzed in the present study were also 
submitted to rosuvastatin quantification by an alternative 
methodology (HPLC-UV), adapted from Sultana, 
Arayne and Naveed (2010). The samples were also 
treated as described in section 2.3, and the results of the 
quantifications are displayed in Table II. 
The paired t-test was then applied to compare the 
two methods. The calculated t (1.29) is less than the 
tabulated t (3.18) at a confidence level of 95% and 3 
degrees of freedom. This indicates no statistical difference 
between the two methods.
CONCLUSIONS
In the present study, a novel methodology for 
rosuvastatin determination in pharmaceutical formulations 
was proposed, based on a charge transfer reaction between 
RSV with quinalizarin. An L.O.Q. of 3.0 mg L-1 is enough 
for the determination of rosuvastatin in pharmaceutical 
formulations, and the method is free from matrix 
interferences. The precision of the method was evaluated 
by ten authentic replicas, and a value of 2.3% (reported as 
relative standard deviation) was found. The comparison 
of this methodology with another method reported in the 
literature (based on HPLC-UV determinations) indicates 
that the proposed method can be considered accurate, since 
no statistical difference was observed between the RSV 
concentrations obtained by both techniques. Furthermore, 
this is a simple method that does not require many steps 
with regard to sample preparation. Such a method may be 
a suitable alternative for the determination of this drug in 
routine analyses.
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